Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Lee, Mei Hsuan ^a,b   Lu, Sheng Nan ^c   Yuan, Yong ^g   Yang, Hwai I ^b,d,e   Jen, Chin Lan ^b   You, San Lin ^b   Wang, Li Yu ^f   L'Italien, Gilbert ^g,h   Chen, Chien Jen ^b,i  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f MACKAY MEDICAL COLLEGE   (Taiwan)

^g Global Health Economics and Outcomes Research   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS C ANTIBODY; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; RNA ANALYSIS; SCORING SYSTEM; VALIDATION PROCESS; VIRUS GENOME; BLOOD; CASE CONTROL STUDY; LIVER TUMOR; PATHOLOGY; PROPENSITY SCORE; VALIDATION STUDY; VIROLOGY;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; HEPATITIS C ANTIBODIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPENSITY SCORE; RNA, VIRAL;

EID: 84900459067     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094760     Document Type: Article

References (36)

1. Lavanchy D (2009) The global burden of hepatitis C. Liver Int 29 Suppl 1: 74-81.
2. Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558-567. (Pubitemid 41196755)
3. Hoofnagle JH, Seeff LB (2006) Peginterferon and ribavirin for chronic hepatitis C. New England Journal of Medicine 355: 2444-2451. (Pubitemid 44903748)
4. Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 127: S35-S50. (Pubitemid 39423368)
5. Lu SN, Su WW, Yang SS, Chang TT, Cheng KS, et al. (2006) Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. International Journal of Cancer 119: 1946-1952.
6. [No authors listed] (1999) EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol 30: 956-961.
7. Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigsby MO, et al. (2004) Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Annals of Internal Medicine 141: 715-717. (Pubitemid 39434844)
8. Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, et al. (2011) The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat 18 Suppl 1: 1-16.
9. Denniston MM, Klevens RM, McQuillan GM, Jiles RB (2012) Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology 55: 1652-1661.
10. Varela M, Reig M, de la Mata M, Matilla A, Bustamante J, et al. (2010) [Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers]. Med Clin (Barc) 134: 569-576.
11. Coffin PO, Scott JD, Golden MR, Sullivan SD (2012) Cost-effectiveness and Population Outcomes of General Population Screening for Hepatitis C. Clinical Infectious Diseases 54: 1259-1271.
12. Deuffic-Burban S, Yazdanpanah Y (2012) It Is Time to Change the Paradigm for Hepatitis C Virus Testing. Clinical Infectious Diseases 54: 1272-1274.
13. Abu Dayyeh BK, Yang M, Fuchs BC, Karl DL, Yamada S, et al. (2011) A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 141: 141-149.
14. Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, et al. (2010) Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 138: 136-146.
15. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, et al. (2001) Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357: 1069-1075. (Pubitemid 32322537)
16. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, et al. (2009) Incidence of hepatocellular carcinoma and associated risk factors in hepatitis Crelated advanced liver disease. Gastroenterology 136: 138-148.
17. Yu ML, Lin SM, Lee CM, Dai CY, Chang WY, et al. (2006) A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology 44: 1086-1097.
18. Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, et al. (2010) Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 59: 1401-1409.
19. Lee MH, Yang HI, Jen CL, Lu SN, Yeh SH, et al. (2011) Community and personal risk factors for hepatitis C virus infection: a survey of 23,820 residents in Taiwan in 1991-2. Gut 60: 688-694.
20. Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH, et al. (2010) Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol 28: 4587-4593.
21. Lee MH, Yang HI, Lu SN, Jen CL, You SL, et al. (2012) Chronic Hepatitis C Virus Infection Increases Mortality From Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study. J Infect Dis 206: 469-477.
22. Huang YC, Huang CF, Chang KC, Hung SF, Wang JH, et al. (2011) Community-based screening for hepatocellular carcinoma in elderly residents in a hepatitis B- and C-endemic area. J Gastroenterol Hepatol 26: 129-134.
23. Lu SN, Wang JH, Chen PF, Tung HD, Tseng PL, et al. (2008) Community-based mass ultrasonographic screening of hepatocellular carcinoma among thrombocytopenic adults. Cancer Epidemiol Biomarkers Prev 17: 1813-1821.
24. Tseng PL, Wang JH, Tung HD, Hung CH, Kee KM, et al. (2010) Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening. J Gastroenterol Hepatol 25: 1426-1434.
25. Yeh SH, Tsai CY, Kao JH, Liu CJ, Kuo TJ, et al. (2004) Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. Journal of Hepatology 41: 659-666.
26. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421-430. (Pubitemid 32844200)
27. Sullivan LM, Massaro JM, D'Agostino RB Sr. (2004) Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med 23: 1631-1660. (Pubitemid 38660414)
28. Volk ML, Tocco R, Saini S, Lok AS (2009) Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 50: 1750-1755.
29. Tsai MC, Kee KM, Chen YD, Lin LC, Tsai LS, et al. (2007) Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country: geographic variations among 502 villages in southern Taiwan. J Gastroenterol Hepatol 22: 92-98.
30. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature Genetics 41: 1100-U1174.
31. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nature Genetics 41: 1105-U1181.
32. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
33. Eurich D, Boas-Knoop S, Bahra M, Neuhaus R, Somasundaram R, et al. (2012) Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Transplantation 93: 644-649.
34. Liu CH, Kao JH (2011) Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives. J Gastroenterol Hepatol 26: 1348-1353.
35. Yu ML, Huang CF, Huang JF, Chang NC, Yang JF, et al. (2011) Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 53: 7-13.
36. (2011) EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 55: 245-264.